These results indicate that PD-L1 antibodies or interference in PD-L1 expression can inhibit tumor growth, destroy tumor tissue morphology, and increase the contents of CD4+ and CD8+ cells, but with eIF5B, such beneficial outcomes can be enhanced. The gene discussed is CD4; the disease is neoplasm.